HoneyBear Biosciences
- Biotech or pharma, therapeutic R&D
HoneyBear Biosciences' core technology platform is CoNectar(TM), a next generation ADC conjugation platform which allows for precise attachment of one or more payloads to optimal locations on any tumor-targeting antibody (e.g. for creating dual-payload ADCs). The enzymatic technology provides orthogonal conjugation of two or more different payloads with pre-determined DAR to the universal carbohydrate moieties on the antibody Fc. No sequence changes are required and the process can be used on existing drug product, including previously manufactured ADCs. The method is enzymatic, rapid and gentle, and has been performed successfully on dozens of antibodies and payloads. HoneyBear is eager to provide access to this unique technology for drug development partners.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}